Buying guide
Lingo vs Fitbit (Charge / Sense / Versa) in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | |
|---|---|---|
| Manufacturer | Abbott | Fitbit |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $110-$160 (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Abbott | 1Fitbit |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 13data-deletion-control, data-sale, cloud-upload, data-retention, location-tracking, training-data-use, biometric-storage, third-party-sharing, Other disclosed, biometric-storage, data-sale, data-deletion-control, data-retention |
| Sources on file | 8 | 22 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Fitbit (Charge / Sense / Versa)
Fitbit (the Charge 6 band, plus the Sense 2 and Versa 4 watches; founded 2007 by James Park and Eric Friedman, acquired by Google in a deal that closed January 2021 for about $2.1B) is the budget-tier cleared anchor of the biometric cohort. The Charge 6, at about $160, brings cleared AFib/ECG (via electrodes on the Sense line), optical heart rate, SpO2, skin temperature, a Sleep Score and Sleep Profile, a Daily Readiness Score, and stress management, with an optional Fitbit Premium subscription (~$9.99/month). It is a Google product line, recorded in the registry as a distinct entity from the Pixel Watch and the Google company, and its health stack shares lineage with the Pixel Watch's Fitbit/Google Health algorithms. The throughline: the strongest cardiologist-validation gradient available at a budget price point, with the AI augmenting genuine biometric sensing.
Machine-readable: this page as markdown.